Evidence map›Paper›PMID 21076854›Full record

ArticleMolecular and cellular biochemistry2011

Mesenteric vascular remodeling in hyperhomocysteinemia.

C Munjal, S Givvimani, N Qipshidze, N Tyagi, J C Falcone, S C Tyagi

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Ablation of MMP9 gene ameliorates paracellular permeability and fibrinogen-amyloid beta complex formation during hyperhomocysteinemia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2014
    Article
  10. Article
  11. Article
  12. Homocysteine imbalance: a pathological metabolic marker.Advances in nutrition (Bethesda, Md.) · 2012
    Review
  13. Hyperhomocysteinemia decreases intestinal motility leading to constipation.American journal of physiology. Gastrointestinal and liver physiology · 2012
    Article
  14. Article
  15. Article
  16. Article
  17. Homocysteine mediated decrease in bone blood flow and remodeling: role of folic acid.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2011
    Article
  18. Remodeling in vein expresses arterial phenotype in hyperhomocysteinemia.International journal of physiology, pathophysiology and pharmacology · 2011
    Article
  19. Synergism between arrhythmia and hyperhomo-cysteinemia in structural heart disease.International journal of physiology, pathophysiology and pharmacology · 2011
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

C MunjalDepartment of Physiology and Biophysics, University of Louisville School of Medicine, Louisville, KY 40202, USA.
S Givvimani
N Qipshidze
N Tyagi
J C Falcone
S C Tyagi
University of Louisville · US

Funding

Mechanism of Vascular Remodeling in HyperhomocysteinemiaR01HL071010 · NHLBI · UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · PI TYAGI, SURESH C. · 2002 to 2010
$2.7M
NHLBI NIH HHS HL-71010NINDS NIH HHS NS-51568
6 · The paper itself

Abstract

Remodeling by its very nature implies synthesis and degradation of extracellular matrix components (such as elastin, collagen, and connexins). Most of the vascular matrix metalloproteinase (MMP) are latent because of the presence of constitutive nitric oxide (NO). However, during oxidative stress peroxinitrite (ONOO-) activates the latent MMPs and instigates vascular remodeling. Interestingly, in mesenteric artery, homocysteine (Hcy) decreases the NO bio-availability, and folic acid (FA, an Hcy-lowering agent) mitigates the Hcy-mediated mesentery artery dysfunction. Dimethylarginine dimethylaminohydrolase-2 (DDAH-2) and endothelial nitric oxide synthase (eNOS) increases NO production. The hypothesis was that the Hcy decreased NO bio-availability, in part, activating MMP, decreasing elastin, DDAH-2, eNOS and increased vasomotor response by increasing connexin. To test this hypothesis,the authors used 12-week-old C57BJ/L6 wild type (WT) and hyperhomocysteinemic (HHcy)-cystathione beta synthase heterozygote knockout (CBS+/-) mice. Blood pressure measurements were made by radio-telemetry. WT and MMP-9 knockout mice were administered with Hcy (0.67 mg/ml in drinking water). Superior mesenteric artery and mesenteric arcade were analyzed with light and confocal microscopy. The protein expressions were measured by western blot analysis. The mRNA levels for MMP-9 were measured by RT-PCR. The data showed decreased DDAH-2 and eNOS expressions in mesentery in CBS-/+ mice compared with WT mice. Immuno-fluorescence and western blot results suggest increased MMP-9 and connexin-40 expression in mesenteric arcades of CBS-/+ mice compared with WT mice. The wall thickness of third-order mesenteric artery was increased in CBS-/+ mice compared to WT mice. Hcy treatment increased blood pressure in WT mice. Interestingly, in MMP-9 KO, Hcy did not increase blood pressure. These results may suggest that HHcy causes mesenteric artery remodeling and narrowing by activating MMP-9 and decreasing DDAH-2 and eNOS expressions, compromising the blood flow, instigating hypertension, and acute abdomen pain.

Indexed as

Abdominal PainAmidohydrolasesAnimalsBlood PressureBlood Pressure Monitoring, AmbulatoryBlotting, WesternConnexinsCystathionine beta-SynthaseDisease Models, AnimalElasticityElastinExtracellular Matrix ProteinsFluorescent Antibody TechniqueGap Junction alpha-5 ProteinHomocysteineHyperhomocysteinemiaAmidohydrolasesConnexinsCystathionine beta-SynthasedimethylargininaseElastinExtracellular Matrix ProteinsGap Junction alpha-5 ProteinHomocysteineMatrix Metalloproteinase 9Mmp9 protein, mouseNitric Oxide Synthase Type IIINitritesNos3 protein, mouseRNA, Messenger

Identifiers

PMID21076854
OpenAlexW1966044450

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.